Results 151 to 160 of about 81,923 (299)

Gilteritinib-associated hand-foot syndrome: a novel dermatologic reaction in refractory FLT3 Acute myeloid leukemia. [PDF]

Leuk Res Rep
Seki JT, Sibai J, Perusini MA, Sibai H.
europepmc   +1 more source

Oral hyperpigmentation as an initial clinical aspect of hand foot syndrome. [PDF]

Braz Dent J, 2022
Santos-Leite ÉGD, Sacramento LV, Santana AM, Dantas JBL, Carrera M, Martins GB.   +5 more
europepmc   +1 more source

Prevalence, Clinical Characteristics, and Factors Associated with Capecitabine-Induced Hand-Foot Syndrome in Patients with Cancer: Evidence from Sudan. [PDF]

Drugs Real World Outcomes
Obeid OK, Yousef BA, Hamadalneel YB, Mustafa MA, Mahmoud AA, Elhag EAA.   +5 more
europepmc   +1 more source

Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. [PDF]

Int J Cancer, 2022
Watts K, Wills C, Madi A, Palles C, Maughan TS, Kaplan R, Al-Tassan NA, Kerr R, Kerr DJ, Houlston RS, Escott-Price V, Cheadle JP.   +11 more
europepmc   +1 more source

Gait Alterations Due to DCC Gene Variants in Individuals with Congenital Mirror Movements

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Congenital Mirror Movement Syndrome (CMMS) involves involuntary movements on one side of the body while voluntary movements are performed on the other side. They disrupt left–right coordination and can be caused by a pathogenic variant in the DCC gene.
Nok‐Yeung Law, Shanie Desrosiers, Sinthiya Sivanesan, Helga Tonkov, Frédéric Charron, Frédéric Bretzner, Myriam Srour, Dorothy Barthélemy   +7 more
wiley   +1 more source

Capecitabine Dosage as an Independent Prognostic Factor for the Development of Hand-Foot Syndrome: A Competing Risk Analysis. [PDF]

Drug Healthc Patient Saf
Chantharakhit C, Patumanond J, Phinyo P, Chai-Adisaksopha C.   +3 more
europepmc   +1 more source

Hand-Foot Syndrome Presentation Post-Capecitabine Treatment in a Black Patient. [PDF]

Cureus, 2022
Whorton AE, Razzak AN, Jha P.
europepmc   +1 more source

Dexrazoxane Protects Against Hand-Foot Syndrome-Like Skin Damage in Pegylated Liposomal Doxorubicin-Treated Mice. [PDF]

J Toxicol
Nishida K, Tanaka J, Hashimoto C, Tanaka M, Kuga T, Shigeta S, Kitatani K.   +6 more
europepmc   +1 more source

Advancements in the diagnosis and management of capecitabine-induced hand-foot syndrome. [PDF]

J Cancer Res Clin Oncol
Chen B, Wang X, Meng L.
europepmc   +1 more source

Analysis of drug-induced hand-foot syndrome using a spontaneous reporting system database. [PDF]

Ther Adv Drug Saf, 2022
Yoshida Y, Sasaoka S, Tanaka M, Matsumoto K, Inoue M, Satake R, Shimada K, Mukai R, Suzuki T, Iwata M, Goto F, Mori T, Mori K, Yoshimura T, Nakamura M.   +14 more
europepmc   +1 more source